Amanta Healthcare LimitedQ1 FY27 Results & Financial Update
Amanta Healthcare Limited: Q1 FY27 standalone results and company financials – revenue ₹68.80 Cr, PAT ₹3.31 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Amanta Healthcare price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Amanta Healthcare Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Amanta Healthcare reported operating revenue of INR 68.80 crore for the quarter ended June 30, 2026 (Q1 FY27), reflecting stable sequential delivery on the back of mature production capacities. Total income for the quarter stood at INR 69.45 crore, bolstered by INR 0.64 crore of other income.
The company posted a profit before tax (PBT) of INR 4.49 crore and a reported net profit (PAT) of INR 3.31 crore for Q1 FY27, after accounting for tax expenses of INR 1.18 crore. Basic earnings per share (EPS) for the quarter stood at INR 0.85.
Operating expenditure for the period remained well-controlled despite inflationary cost pressures. Total expenditure of INR 64.95 crore comprised INR 23.47 crore in material costs consumed, INR 12.18 crore in employee benefit expenses, and INR 21.68 crore in other operating and overhead expenses.
Financing costs for the quarter were recorded at INR 6.00 crore, reflecting debt servicing obligations associated with past capital expenditures, while depreciation and amortization expenses stood at INR 4.69 crore.
The quarter marked a crucial operational milestone with the commissioning of the company's 10.8 MW captive solar power plant by the end of Q1 FY27, establishing a structural avenue for lower energy overheads starting from subsequent quarters in FY27.
Management highlighted that upcoming capacity expansions across high-margin SteriPort LVP and SVP lines are slated to commence commercial operations from Q2 FY27 onwards, setting the stage for accelerated revenue and margin scale.
Profit after tax was ₹3.31 Cr for the reported quarter. EPS was ₹0.85 for the reported quarter.
01 · Business model
What does Amanta Healthcare do?
Amanta Healthcare Limited is a niche pharmaceutical company with over 30 years of operating legacy specializing in sterile liquids, large volume parenterals (LVPs), and small volume parenterals (SVPs).
The company manufactures via advanced technologies including Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch-Blow Moulding (ISBM) at its single integrated WHO-GMP certified facility located in Kheda, Gujarat, spanning 66,852 square meters.
Its product portfolio encompasses six therapeutic segments—Fluid Therapy, Formulations, Diluents & Injectables, Ophthalmic, Respiratory Solutions, and Irrigation Solutions—marketed domestically under the SteriPort generic brand through 320+ distributors and exported across 21 countries.
Amanta commands a 50% to 60% domestic market share in its ISBM-enabled polypropylene bottle segment, backed by a workforce of 506 regular employees and approximately 1,700 contract workers.
02 · Historical context
What shaped the business before this quarter
Amanta established its sterile liquids business over 30 years ago and became the first manufacturer in India to transition from conventional Form-Fill-Seal packaging to Injection Stretch-Blow Moulding (ISBM) technology for polypropylene IV bottles.
Since FY23, the company aggressively de-leveraged its balance sheet, reducing its debt-to-equity ratio significantly from 3.43x in FY23 down to 1.06x in FY26 while trimming total borrowings by over INR 30 crore.
Over the period leading up to FY26, Amanta achieved high capacity utilization rates of 93% for LVP, 98% for SVP, and 90% for SteriPort, necessitating an expanded capital expenditure outlay of INR 120 crore in FY26 to scale up manufacturing lines.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹68.80 Cr |
| Total income | ₹69.45 Cr |
| Profit before tax | ₹4.49 Cr |
| Profit after tax | ₹3.31 Cr |
| EPS | ₹0.85 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Fluid therapy products—anchored by the flagship SteriPort brand manufactured using ISBM technology—contributed 63% of overall revenues, benefiting from high hospital demand across intensive care and critical care applications.
Formulations contributed 17% of revenue, diluents and injectables accounted for 9%, while respiratory solutions, irrigation solutions, and ophthalmic products together formed the balance of domestic and export sales.
What drove margins
Cost of materials consumed was contained at INR 23.47 crore for Q1 FY27, with key polymer raw materials such as LDPE (27.5% share) and polypropylene (12.5% share) sourced primarily from South Korea and Thailand.
The newly commissioned 10.8 MW captive solar power plant, implemented at a total cost of INR 34.8 crore, is projected to deliver annual power cost savings of approximately INR 9 crore, supporting future EBITDA margin expansion.
05 · Demand, customers & order book
Where demand is coming from
SteriPort products are utilized across oncology, critical care, pediatrics, intensive care, and anesthesia departments in hospitals, backed by strong repeat demand and high asset utilization.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Operates 4 LVP manufacturing lines with an installed capacity of 12.28 crore units, including 2 lines dedicated to SteriPort ISBM bottles which command a 50% to 60% domestic market share.
Operates 3 SVP manufacturing lines with an installed capacity of 20.91 crore units, focusing on high-margin inhalation solutions (respules), OTC formulations, and preservative-free unit doses.
Geography and market mix
Domestic branded generics are distributed via a network of over 320 distributors and 96 sales personnel, while international exports span 21 countries and 120 registered product jurisdictions across emerging and semi-regulated markets.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The company operates a single WHO-GMP certified manufacturing complex in Kheda, Gujarat, maintaining high asset utilization across parenteral lines heading into Q1 FY27.
Projects, capex and execution
Upcoming expansions scaling SteriPort and SVP capacities by 5.39 crore and 10.78 crore units respectively are scheduled to commence commercial operations from Q2 FY27 and Q4 FY27, expected to add INR 110-120 crore in annual incremental revenue.
08 · Strategy & new businesses
How the company is trying to change its growth mix
The 10.8 MW captive solar power plant was successfully commissioned at the end of Q1 FY27 via an INR 5.8 crore equity contribution and term loan financing, lowering the company's carbon footprint and structural power costs.
09 · Reported developments
What changed operationally
Successful commissioning of the 10.8 MW captive solar plant at the close of Q1 FY27, positioning the company for substantial energy cost reductions from FY27 onwards.
10 · Pressure points & risks
What is not going smoothly
Polymer sourcing remains concentrated geographically, with South Korea accounting for 77.2% of plastic purchases and Thailand accounting for 22.8%.
11 · Items worth noticing
The line items that can distort a quick read
Recorded tax expenses of INR 1.18 crore for Q1 FY27 on a PBT of INR 4.49 crore, resulting in a PAT of INR 3.31 crore.
12 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Net working capital stood at 141 days as of FY26, reflecting the inventory and receivables structure inherent in pharmaceutical manufacturing and distribution.
Capital allocation & funding
Finance costs of INR 6.00 crore for Q1 FY27 reflect outstanding term debt obligations, which include funding for the INR 34.8 crore captive solar project and prior capital expenditure programs.
13 · Management guidance & targets
What management is targeting from here
Management has stated an aspiration to achieve a revenue CAGR of 20%+ and EBITDA margins of 25%+ over the next two years, driven by capacity expansions and solar power cost savings.
14 · Beyond the numbers
What changed beyond the numbers
Reported update
Board Governance
The board comprises experienced professionals including Chairman and Managing Director Mr. Bhavesh Patel, non-executive directors, and independent directors with backgrounds in chartered accounting, investment banking, and chemical engineering.
15 · Previous-quarter changes
What changed since the previous quarter
Transitioned from Q4 FY26 into Q1 FY27 with stable operating revenues of INR 68.80 crore while completing the installation of the 10.8 MW captive solar energy facility.
16 · Key Q&A
The quarter, answered directly
What does Amanta Healthcare do?
Amanta Healthcare Limited is a niche pharmaceutical company with over 30 years of operating legacy specializing in sterile liquids, large volume parenterals (LVPs), and small volume parenterals (SVPs).
What is the clearest takeaway from Q1 FY27?
Amanta Healthcare reported operating revenue of INR 68.80 crore for the quarter ended June 30, 2026 (Q1 FY27), reflecting stable sequential delivery on the back of mature production capacities. Total income for the quarter stood at INR 69.45 crore, bolstered by INR 0.64 crore of other income.
What drove revenue or demand?
Fluid therapy products—anchored by the flagship SteriPort brand manufactured using ISBM technology—contributed 63% of overall revenues, benefiting from high hospital demand across intensive care and critical care applications.
What mattered most for margins or profitability?
Cost of materials consumed was contained at INR 23.47 crore for Q1 FY27, with key polymer raw materials such as LDPE (27.5% share) and polypropylene (12.5% share) sourced primarily from South Korea and Thailand.
What changed operationally beyond the headline numbers?
The company operates a single WHO-GMP certified manufacturing complex in Kheda, Gujarat, maintaining high asset utilization across parenteral lines heading into Q1 FY27.
What is management guiding or targeting from here?
Management has stated an aspiration to achieve a revenue CAGR of 20%+ and EBITDA margins of 25%+ over the next two years, driven by capacity expansions and solar power cost savings.
17 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
18 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Expansion Commercialization: Monitor the commercial commissioning of new LVP and SVP capacity lines starting in Q2 FY27 and their subsequent contribution to revenue growth.
- 02
Energy Cost Realization: Track the realization of projected annual power cost savings of INR 9 crore from the newly commissioned captive solar power plant on quarterly EBITDA margins.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.